AI assistant
Sending…
DEXCOM INC — Director's Dealing 2020
Apr 27, 2020
30198_dirs_2020-04-27_e5bd5f12-3ae4-4dd0-bf1b-32db7ad9ee3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2020-04-23
Reporting Person: DOUBLEDAY RICHARD (EVP Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-04-23 | Common Stock | S | 1530 | $318.57 | Disposed | 7653 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 51482 | Direct |
Footnotes
F1: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
More from DEXCOM INC
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 15
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 17